Jazz Pharmaceuticals (Germany) Performance
| J7Z Stock | EUR 116.85 1.15 0.97% |
On a scale of 0 to 100, Jazz Pharmaceuticals holds a performance score of 11. The company retains a Market Volatility (i.e., Beta) of 0.7, which attests to possible diversification benefits within a given portfolio. As returns on the market increase, Jazz Pharmaceuticals' returns are expected to increase less than the market. However, during the bear market, the loss of holding Jazz Pharmaceuticals is expected to be smaller as well. Please check Jazz Pharmaceuticals' expected short fall, daily balance of power, and the relationship between the downside variance and kurtosis , to make a quick decision on whether Jazz Pharmaceuticals' current trending patterns will revert.
Risk-Adjusted Performance
11 of 100
Weak | Strong |
Good
Compared to the overall equity markets, risk-adjusted returns on investments in Jazz Pharmaceuticals plc are ranked lower than 11 (%) of all global equities and portfolios over the last 90 days. Despite nearly fragile basic indicators, Jazz Pharmaceuticals reported solid returns over the last few months and may actually be approaching a breakup point. ...more
| Begin Period Cash Flow | 1.1 B | |
| Total Cashflows From Investing Activities | -5.2 B |
Jazz |
Jazz Pharmaceuticals Relative Risk vs. Return Landscape
If you would invest 9,782 in Jazz Pharmaceuticals plc on September 23, 2024 and sell it today you would earn a total of 1,903 from holding Jazz Pharmaceuticals plc or generate 19.45% return on investment over 90 days. Jazz Pharmaceuticals plc is currently producing 0.2892% returns and takes up 2.0051% volatility of returns over 90 trading days. Put another way, 17% of traded stocks are less volatile than Jazz, and 95% of all traded equity instruments are likely to generate higher returns over the next 90 trading days. Expected Return |
| Risk |
Jazz Pharmaceuticals Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Jazz Pharmaceuticals' investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as Jazz Pharmaceuticals plc, and traders can use it to determine the average amount a Jazz Pharmaceuticals' price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = 0.1443
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | J7Z | |||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns |
Estimated Market Risk
| 2.01 actual daily | 17 83% of assets are more volatile |
Expected Return
| 0.29 actual daily | 5 95% of assets have higher returns |
Risk-Adjusted Return
| 0.14 actual daily | 11 89% of assets perform better |
Based on monthly moving average Jazz Pharmaceuticals is performing at about 11% of its full potential. If added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Jazz Pharmaceuticals by adding it to a well-diversified portfolio.
Jazz Pharmaceuticals Fundamentals Growth
Jazz Stock prices reflect investors' perceptions of the future prospects and financial health of Jazz Pharmaceuticals, and Jazz Pharmaceuticals fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Jazz Stock performance.
| Return On Equity | -0.0056 | |||
| Return On Asset | 0.053 | |||
| Profit Margin | (0.01) % | |||
| Operating Margin | 0.27 % | |||
| Current Valuation | 13.72 B | |||
| Shares Outstanding | 62.97 M | |||
| Price To Earning | 15.29 X | |||
| Price To Book | 3.49 X | |||
| Price To Sales | 2.60 X | |||
| Revenue | 3.09 B | |||
| EBITDA | 718.41 M | |||
| Cash And Equivalents | 833.95 M | |||
| Cash Per Share | 14.72 X | |||
| Total Debt | 6.02 B | |||
| Debt To Equity | 64.50 % | |||
| Book Value Per Share | 43.65 X | |||
| Cash Flow From Operations | 778.51 M | |||
| Earnings Per Share | (0.26) X | |||
| Total Asset | 12.3 B | |||
About Jazz Pharmaceuticals Performance
By analyzing Jazz Pharmaceuticals' fundamental ratios, stakeholders can gain valuable insights into Jazz Pharmaceuticals' financial health, operational efficiency, and overall profitability, helping them make informed investment and management decisions. For instance, if Jazz Pharmaceuticals has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if Jazz Pharmaceuticals has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements.
Jazz Pharmaceuticals plc, a biopharmaceutical company, identifies, develops, and commercializes pharmaceutical products for various unmet medical needs in the United States, Europe, and internationally. Jazz Pharmaceuticals plc has licensing and collaboration agreements with ImmunoGen, Inc. Codiak BioSciences, Inc. Pfenex, Inc. and XL-protein GmbH. JAZZ PHARMACEUT operates under Biotechnology classification in Germany and is traded on Frankfurt Stock Exchange. It employs 1460 people.Things to note about Jazz Pharmaceuticals plc performance evaluation
Checking the ongoing alerts about Jazz Pharmaceuticals for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Jazz Pharmaceuticals plc help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| The company has €6.02 Billion in debt which may indicate that it relies heavily on debt financing | |
| The company reported the revenue of 3.09 B. Net Loss for the year was (329.67 M) with profit before overhead, payroll, taxes, and interest of 2.88 B. | |
| Over 93.0% of the company shares are owned by institutional investors |
- Analyzing Jazz Pharmaceuticals' financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Jazz Pharmaceuticals' stock is overvalued or undervalued compared to its peers.
- Examining Jazz Pharmaceuticals' industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Jazz Pharmaceuticals' management team can have a significant impact on its success or failure. Reviewing the track record and experience of Jazz Pharmaceuticals' management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Jazz Pharmaceuticals' stock. These opinions can provide insight into Jazz Pharmaceuticals' potential for growth and whether the stock is currently undervalued or overvalued.
Complementary Tools for Jazz Stock analysis
When running Jazz Pharmaceuticals' price analysis, check to measure Jazz Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Jazz Pharmaceuticals is operating at the current time. Most of Jazz Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Jazz Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Jazz Pharmaceuticals' price. Additionally, you may evaluate how the addition of Jazz Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.
| Headlines Timeline Stay connected to all market stories and filter out noise. Drill down to analyze hype elasticity | |
| Portfolio Backtesting Avoid under-diversification and over-optimization by backtesting your portfolios | |
| Insider Screener Find insiders across different sectors to evaluate their impact on performance | |
| USA ETFs Find actively traded Exchange Traded Funds (ETF) in USA | |
| Equity Forecasting Use basic forecasting models to generate price predictions and determine price momentum | |
| Top Crypto Exchanges Search and analyze digital assets across top global cryptocurrency exchanges | |
| Odds Of Bankruptcy Get analysis of equity chance of financial distress in the next 2 years | |
| Commodity Directory Find actively traded commodities issued by global exchanges | |
| Positions Ratings Determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance |